Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Minimally invasive techniques including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026–2033 in the Uterine Fibroid Market

    80% confidence
  • The Uterine Fibroid Market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025E and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% during 2026-2033

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence
  • Surgical Procedures dominated with 38.45% in 2025 due to their proven effectiveness, widespread availability, and established clinical use

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • Surgical Procedures dominated with 38.45% in 2025 due to their proven effectiveness, widespread availability, and established clinical use

    80% confidence
  • The uterine fibroid market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com